Trial · NCT03047395
Adverse events396
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 396
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Risankizumab 150 mg | 360 | 2,170 | 384 |
| other | NASOPHARYNGITIS | Infections and infestations | Risankizumab 150 mg | 480 | 2,170 | 833 |
| other | UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | Risankizumab 150 mg | 312 | 2,170 | 467 |
| other | ARTHRALGIA | Musculoskeletal and connective tissue disorders | Risankizumab 150 mg | 217 | 2,170 | 267 |
| other | BACK PAIN | Musculoskeletal and connective tissue disorders | Risankizumab 150 mg | 124 | 2,170 | 142 |
| other | HEADACHE | Nervous system disorders | Risankizumab 150 mg | 134 | 2,170 | 211 |
| other | HYPERTENSION | Vascular disorders | Risankizumab 150 mg | 227 | 2,170 | 245 |
| serious | ANAEMIA | Blood and lymphatic system disorders | Risankizumab 150 mg | 3 | 2,170 | 4 |
| serious | FEBRILE NEUTROPENIA | Blood and lymphatic system disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | HAEMOLYSIS | Blood and lymphatic system disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | PANCYTOPENIA | Blood and lymphatic system disorders | Risankizumab 150 mg | 2 | 2,170 | 2 |
| serious | ACUTE CORONARY SYNDROME | Cardiac disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | ACUTE MYOCARDIAL INFARCTION | Cardiac disorders | Risankizumab 150 mg | 13 | 2,170 | 13 |
| serious | ANGINA PECTORIS | Cardiac disorders | Risankizumab 150 mg | 2 | 2,170 | 2 |
| serious | ANGINA UNSTABLE | Cardiac disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | AORTIC VALVE INCOMPETENCE | Cardiac disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | ARRHYTHMIA | Cardiac disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | ARTERIOSCLEROSIS CORONARY ARTERY | Cardiac disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
| serious | ATRIAL FIBRILLATION | Cardiac disorders | Risankizumab 150 mg | 9 | 2,170 | 9 |
| serious | ATRIAL FLUTTER | Cardiac disorders | Risankizumab 150 mg | 1 | 2,170 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03047395/events